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Abstract
Background: To investigate the impact of high circulating AMH on the outcome of CC ovulation induction in
women with PCOS.
Methods: This prospective cohort observational study included 81 anovulatory women with PCOS who underwent
213 cycles of CC ovarian stimulation. Serum AMH concentrations were measured on cycle day 3 before
the commencement of CC in the first cycle, which were compared between responders and CC-resistant anovulation
(CRA). Logistic regression analysis was applied to study the value of serum AMH for the prediction of ovarian
responsiveness to CC stimulation. The receiver-operating characteristic (ROC) curve was used to evaluate the
prognostic value of circulating AMH.
Main outcome measures: Serum AMH levels.
Results: Women who ovulated after CC therapy had a significantly lower AMH compared with the CRA (5.34 ± 1.97
vs.7.81 ± 3.49, P < 0.001). There was a significant gradient increase of serum AMH levels with the increasing dose of CC
required to achieve ovulation (P < 0.05). In multivariate logistic regression analysis, AMH was an independent predictor
of ovulation induction by CC in PCOS patients. ROC curve analysis showed AMH to be a useful predictor of ovulation
induction by CC in PCOS patients, having 92 % specificity and 65 % sensitivity when the threshold AMH concentration
was 7.77 ng/ml.
Conclusion: Serum AMH may be clinically useful to predict which PCOS women are more likely to respond to CC
treatment and thus to direct the selection of protocols of ovulation induction.
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Background
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder in women of reproductive age, with a
prevalence of approximately 5–10 %. PCOS is the major
cause of anovulatory infertility [1]. The recent studies
suggest that anovulation results from ovarian follicle ab-
normalities in PCOS patitents are 2-fold [2, 3]. First,
early follicular growth is excessive, thus women with
PCOS are characterized by an excessive number of small
antral follicles (2- to 3-fold that of normal ovaries). Sec-
ondly, the selection of one follicle from the increased
pool of selectable follicles and its further maturation to a
dominant follicle does not occur. This second abnormal-
ity in the folliculogenesis is named the follicular arrest
(FA) and explains the ovulatory disorder of PCOS.
Although the FA has not received yet a clear and unani-
mous explanation, Anti-Müllerian hormone (AMH) is
considered as important contributors to this abnormal-
ity [4, 5].
AMH is producted specifically by granulose cells of
early developing pre-antral and small antral follicles in
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the ovary. Serum AMH levels in women with PCOS are
2- to 3-fold higher than in ovulatory women with nor-
mal ovaries [6, 7], which corresponds to the 2- to 3-fold
increase in the number of small follicles seen in PCOS.
The increased AMH has been hypothesized may reduce
follicle sensitivity to FSH and oestradiol production, thus
preventing follicle selection, resulting in follicle arrest at
the small antral phase with the failure of dominance.
At present, the treatment of oligo- or anovulatory
infertility is referred to as induction of ovulation. Clomi-
phene citrate (CC) is the treatment of first choice for
ovulation induction in anovulatory women with PCOS.
There are 20–25 % of women, however, remain anovula-
tory after receiving CC medication [8] and the exact
cause of CC failure in some patients remain uncertain.
Indentifying factors that determine the response of
women with PCOS to CC will help selecting patients
who are likely to benefit from this treatment, thus avoid-
ing fruitless treatment and improving success rates.
Recently, AMH has been characterized as a promising
novel clinical marker of ovarian reserve and predicting
ovarian response to gonadotrophins during in vitro
fertilization (IVF) in women without PCOS [9–11]. In
PCOS women, we recent found AMH levels on day 3 of
the IVF stimulation cycle still positively predict ovarian
response to gonadotrophins [12]. However, different
from our study, the predictive meaning of AMH was
considered different between women with and without
PCOS, for the authors found circulating AMH levels
were negatively correlated with ovarian response to go-
nadotrophins during ovary induction in PCOS women
[13]. Hence, the results of hitherto published studies are
seemed not entirely in consensus. So we designed a
study to investigate whether serum AMH has a role in
predicting ovary response to CC treatment in a large
cohort of infertile women with PCOS.
Methods
Patients
Subjects included 81 anovulatory women with PCOS
who were referred to our department for ovulation in-
duction between February 2012 and June 2014. The
diagnosis of PCOS was based on the Rotterdam criteria,
in which at least two of the following three criteria were
met: oligomenorrhea or amenorrhea, hyperandrogenae-
mia, and sonographic appearance of polycystic ovaries
[14]. Oligomenorrhoea was defined as cycles lasting
longer than 35 days. Amenorrhea was defined as
cycles lasting longer than 6 months. Hyperandrogen-
ism was diagnosed either clinically (acne/hirsutism)
and/or biochemically (testosterone >0.7 ng/ml). The
ovary was considered polycystic on ultrasound scan if
it contained ≥12 follicles (2–9 mm in diameter) and/or
measured >10 ml in volume. All patients presented
with anovulatory cycles for at least 2 years. The inclu-
sion criteria included: patients 35 years old or younger,
BMI ≤30 kg/m without previous ovulation induction
and partners with normal semen parameters. No
PCOS patient had evidence of hyperprolactinemia,
Cushing’s syndrome, congenital adrenal hyperplasia or
androgen-secreting tumors.
Ethical approval
This study was approved by the Ethics Committee of
The Second Affiliated Hospital of Xi an Jiaotong Uni-
versity. All participants provided their informed consent
before their involvement in this study.
Clomiphene citrate treatment
All women received an initial dose of 50 mg/d CC from
cycle d3 until d7 after spontaneous or progestagen-
induced withdrawal bleeding. In the case of an absent
ovarian response, daily dosage was increased to 100 mg
in the following cycles. If ovulation occurred, the dose
remained unaltered during subsequent cycles. First ovu-
lation was used as the end point. The duration of all
patients included in the study was at least three treat-
ment cycles. Ovulation was assessed by midluteal serum
progesterone measurement (levels >10 ng/ml indicating
ovulation) combined with transvaginal sonographic
monitoring of follicle growth until the appearance of a
preovulatory follicle (mean diameter ≥18 mm) and sub-
sequent follicle rupture. Responders were defined as
patients who ovulated during CC therapy, independent
of the dose administered. Failure to ovulate in three CC
cycles despite stimulation with the maximum dose
(100 mg/d) was referred to as CC-resistant anovulation
(CRA). Clinical pregnancy was defined as the presence
of a gestational sac with cardiacactivity as detected by
transvaginal ultrasound after 35 days of ovulation.
Hormone assays
Blood samples were collected on cycle day 3 before the
commencement of CC in the first cycle of treatment to
measure baseline serum concentrations of AMH. AMH
was measured by using a second-generation enzyme-
linked immunosorbent assay (ELISA) (Immunotech
Beckman Coulter Laboratories, Villepinte, France). The
analytical sensitivity of this assay is 0.14 ng/mL. Intra-
and inter-assay coefficients of variation were ≤12.3 and
≤14.2 %, respectively.
Serum other hormonal concentrations including
luteinizing hormone (LH), follicle stimulating hormone
(FSH), testosterone (T), insulin and progesterone were
measured using electrochemiluminescence immunoassay
(Roche Diagnostics GmbH, Mannheim, Germany). Insulin
resistance, defined by the homeostasis model assessment
insulin resistance index (HOMA-IR), was calculated using
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the following equation: HOMA-IR = fasting insulin (IU/
ml) × fasting glucose (mmol/L)/22.5 [15].
Transvaginal scan
In the same morning of the blood tests, a transvaginal
ultrasound scan was performed to assess the ovarian vol-
ume (milliliters), and antral follicles count (AFC). The
volume of each ovary was calculated by measuring the
ovarian diameters (D) in three perpendicular directions
and applying the formula for an ellipsoid: D1 × D2 ×
D3 × 0.5236. For the determination of the AFC, we cal-
culated small follicles with a diameter between 2 and
9 mm, following the recommendations as described pre-
viously [16].
Statistical analysis
The Statistical Package for Social Sciences (SPSS 17.0,
Chicago) was used for statistical analysis. Differences
between responders and nonresponders were tested
using the t-test, nonparametric test (Mann–Whitney U)
and χ2-test as appropriate. Spearman’s correlation co-
efficient was calculated to evaluate the relation of AMH
to other characteristics of PCOS. Using the results of the
ROC analysis, we defined an appropriate threshold level
for AMH and determined the sensitivity and specificity
of that threshold. Logistic regression analysis was ap-
plied to study the value of serum AMH and other
study variables for the prediction of ovarian respon-
siveness to CC stimulation. P < 0.05 was considered
statistically significant. Multiple logistic regression
analysis with forward selection of parameters was ap-
plied with P < 0.10 for entry.
Results
The study included 81 anovulatory women with PCOS
who received 213 cycles of CC ovulation induction.
Patient characteristics are shown in Table 1. Of the 81
women included in the study, 43 (53.1 %) ovulated dur-
ing ovulation induction with CC 50 mg/d. This number
increased to 52 (64.2 %) after increasing CC dose up to
the100 mg/d, 29(35.8 %) remaining anovulatory were
considered CRA (Fig. 1). A total of 26(32.1 %) women
conceived during up to three cycles of CC treatment. Of
the 213 CC cycles, ovulation occurred in 114 cycles
(53.5 %) and pregnancy in 26 cycles (12.2 %).
Women were divided into two groups based on their
response to clomiphene citrate treatment: CC responders
(n = 52) and CRA (n = 29). Patients who ovulated had a
significantly lower serum AMH concentration compared
with nonresponders (5.34 ± 1.97 vs.7.81 ± 3.49, P < 0.001).
AFC and ovarian volume from responders group were
statistically significantly lower than from the CRA group
(P < 0.05). There were no significant differences between
the groups in mean age, BMI, FSH, LH, LH/FSH, T and
HOMA-IR (Table 1). In addition, patients who conceived
had a significantly lower serum AMH concentrations com-
pared with that of those who did not conceive (4.81 ± 2.06
vs. 6.89 ± 2.95 ng/ml, P < 0.01) (Table 2). When CC-
resistant patients were excluded from analysis of pregnancy,
serum AMH concentrations were comparable in women
achieving pregnancy (n = 26) and those not conceiving
(n = 26) (4.81 ± 2.06 ng/ml vs 5.67 ± 1.76 ng/ml, P > 0.05).
Spearman’s correlations between serum AMH concen-
trations and other characteristics of PCOS showed AMH
significantly correlated with serum LH (r = 0.253, P < 0.05),
ovarian volume (r = 0.297, P < 0.01) and AFC (r = 0.296,
P < 0.01). No statistically significant correlation between
Table 1 Baseline characteristics of 81 anovulatory women with PCOS who received CC ovulation induction, and separated for
women who do (responders) or do not ovulate (CRA) after CC induction of ovulation
Variable All participants CC responders CRA P value
n = 81 n = 52 n = 29
Age (years) 26.62 ± 2.53 26.98 ± 2.48 25.97 ± 2.53 NS
BMI (kg/m2) 23.79 ± 2.78 23.53 ± 2.81 24.24 ± 2.71 NS
LH(IU/L) 8.29 ± 2.37 8.01 ± 2.29 8.77 ± 2.49 NS
FSH(IU/L) 5.73 ± 1.19 5.79 ± 1.28 5.62 ± 1.03 NS
LH/FSH 1.52 ± 0.59 1.46 ± 0.58 1.63 ± 0.62 NS
T(ng/ml) 0.56 ± 0.25 0.55 ± 0.23 0.58 ± 0.29 NS
HOMA-IR 3.18 ± 1.92 3.11 ± 2.16 3.31 ± 1.41 NS
Ovarian volume (ml) 10.43 ± 1.58 9.7 ± 1.32 10.49 ± 1.74 <0.05
AFC (n) 16.11 ± 3.71 15.44 ± 3.17 17.31 ± 4.33 <0.05
AMH 6.22 ± 2.8 5.34 ± 1.97 7.81 ± 3.49 <0.001
Note: Values are mean ± SD unless otherwise indicated
CRA CC-resistant anovulation, BMI body mass index, LH luteinizing hormone, FSH follicle stimulating hormone, T testosterone, HOMA-IR the homeostasis model
assessment insulin resistance index, AFC antral follicles count, AMH antimüllerian hormone, NS Not statistially significant
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serum AMH and BMI, FSH, LH/FSH, T and HOMA-IR
could be found (Table 3). Univariate logistic regression
analysis showed that AMH, AFC and ovarian volume were
significant predictors of ovarian response to CC stimula-
tion. For the multivariate logistic regression analysis using
stepwise forward selection on all variables, AMH was
selected in the final model, while mean ovarian volume
and AFC were not (date were not shown).
Figure 2 presents ROC for the sensitivity and spe-
cificity of the AMH at different levels in predicting
no ovulation after CC therapy. The AMH shows a
ROCAUC of 0.813 for no ovulation, indicating a
useful potential for predicting CRA. Considering a
serum AMH concentration of 7.77 ng/ml as cut-off,
the sensitivity and specificity of predicting no ovula-
tion were 92 and 65 % respectively. With this cut-off
(7.77 ng/ml), the outcomes of CC ovarian stimula-
tion were compared between cycles with high AMH
vs. low AMH levels. Patients with AMH levels less
than 7.77 ng/ml had significantly higher ovulation
and pregnancy rates than those with AMH of
7.77 ng/ml or greater. In addition, patients with high
AMH levels had significantly higher LH, ovarian volume
and AFC (Table 4).
AMH and dose of CC
The mean serum concentration of AMH was com-
pared between PCOS patients who responded to CC
50 mg (n = 43) vs those who responded to the higher
dose 100 mg (n = 9). The results showed a significant
Fig. 1 Distribution of women who do or do not ovulate after CC
induction of ovulation in incremental daily doses of 50, or 100 mg
for 5 subsequent days. A total of 29 women (35.8 % of the overall
study group) remain anovulatory
Table 2 Comparison the characteristics of PCOS women who
conceived on CC treatment (n = 26) and those who did not
conceive (n = 55)
Pregnant Nonpregnant P value
n = 26 n = 55
Age (years) 27.08 ± 2.23 26.40 ± 2.65 NS
BMI (kg/m2) 23.46 ± 2.83 23.94 ± 2.77 NS
LH(IU/L) 8.05 ± 2.12 8.40 ± 2.50 NS
FSH(IU/L) 5.55 ± 1.3 5.82 ± 1.14 NS
LH/FSH 1.55 ± 0.65 1.51 ± 0.57 NS
T(ng/ml) 0.55 ± 0.22 0.58 ± 0.27 NS
HOMA-IR 3.02 ± 1.35 3.27 ± 2.69 NS
Ovarian volume (ml) 9.52 ± 1.28 10.27 ± 1.48 <0.05
AFC (n) 15.04 ± 2.82 16.62 ± 3.98 NS
AMH 4.81 ± 2.06 6.89 ± 2.95 <0.01
Table 3 Spearman’s correlations between plasma AMH and
other factors in women with PCOS
Variable r P value
Age (years) −0.012 NS
BMI (kg/m2) 0.027 NS





Ovarian volume (ml) 0.297 <0.01
AFC (n) 0.296 <0.01
Fig. 2 Receiver operating characteristic curve of AMH to predict
clomiphene citrate resistance in patients with polycystic ovary syndrome
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(P < 0.05) increase of serum AMH level with the in-
creasing dose of CC (Table 5).
Discussion
Since the increased AMH would impair the action of
FSH and contribute to the FA of PCOS, this evidence
has led us to hypothesise that there is a subgroup of
women with PCOS who have the higher levels of AMH
and who are the more resistant to CC treatment. In this
study, we really proved that patients with high AMH
level are less likely to respond to CC treatment. Further-
more, we have identified a cut-off level of AMH
(7.77 ng/ml), above which the chances of ovulation seem
to be significantly reduced. These observations suggest
that high AMH values reflect more impaired disruption
in folliculogenesis and granulosa cell function.
However, it may seem paradoxical that serum AMH
concentrations are known to positively predict ovarian
response to gonadotrophin stimulation during IVF. For
women with high AMH levels are considered to predict
excessive ovarian response to gonadotropin. Meanwhile,
low AMH levels indicative of a diminished ovarian re-
serve, is associated with poor response [17, 18]. Amer
SA et al. [13] explained the contradiction may be due to
the different spectrum of circulating AMH in women
with and without PCOS. Since AMH levels were signifi-
cantly increased in women with PCOS, they considered
levels above the optimum AMH values are associated
with poor ovarian response to stimulation. It is interest-
ing to note that, in contrast to Amer SA’s opinion, Kaya
et al. [19] and our previous study [12] found a positive
association between serum AMH levels and ovarian re-
sponsiveness to gonadotrophins during IVF in women
with PCOS. In that study as serum AMH levels
increased, an increase in estrodiol levels on the day
of hCG administration and the number of retrieved
oocytes were observed, while the total dose of the
gonadotrophins was significantly decreased. Thus, we
suppose the predictive role of AMH is different in
ovarian responsiveness to ovulation induction with
CC and ovarian hyperstimulation with gonadotrophins
for IVF treatment, because the goal of stimulation in
women with anovulation is different than that in
women undergoing IVF.
It is sopposed that in anovulatory women with PCOS,
increasing the serum FSH level may reduce the AMH
excess, thus relieving its inhibition on the follicular
growth, and allowing the emergence of a dominant
follicle [20]. In ovulation induction the aim should be to
achieve the ovulation of a single follicle, CC thus consti-
tutes the first line treatment of choice in PCOS women.
Chronic low-dose gonadotrophins (with a starting dose
37.5 or 50U daily) have been used to stimulate ovulation
in women who fail to ovulate with CC. However, both
CC and low-dose gonadotrophins make the serum FSH
levels increased gently and may be not enough to reduce
intra-ovarian AMH to a level consistent with resump-
tion of ovulation in women with high AMH level.
Therefore, as expected the patient with higher AMH
were more deeply inhibited and more likely to remain
anovulatory after ovulation induction. The aim of IVF
treatment, however, is normally designed to promote
multifollicular development and as such will usually
employ higher doses of FSH (with a starting dose at least
Table 4 Comparison of PCOS women with high vs low AMH using a cutoff value of 7.77 ng/ml
AMH <7.77 ng/ml AMH ≥7.77 ng/ml P value PPV NPV
n = 59 n = 22
Age (years) 26.68 ± 2.31 26.45 ± 3.08 NS
BMI (kg/m2) 23.54 ± 2.80 24.45 ± 2.67 NS
LH(IU/L) 7.92 ± 2.26 9.28 ± 2.43 <0.05
FSH(IU/L) 5.73 ± 1.16 5.73 ± 1.29 NS
LH/FSH 1.45 ± 0.55 1.72 ± 0.66 NS
T(ng/ml) 0.56 ± 0.22 0.56 ± 0.33 NS
HOMA-IR 3.12 ± 2.09 3.24 ± 1.39 NS
Ovarian volume (ml) 9.72 ± 1.31 10.69 ± 1.82 <0.01
AFC (n) 15.24 ± 3.06 18.45 ± 4.31 <0.01
Ovulation/patient 46/81(57 %) 6/81(7 %) <0.001 88.5 55.2
Pregnancy/patient 23/81(28 %) 3/81(4 %) <0.01 88.4 34.5
Table 5 Serum AMH concentrations in PCOS patients achieving








Not ovulated, n (%) Ovulated, n (%)
50 38 (46.9) 43 (53.1) 5.07 ± 1.8 —
100 29 (76.3) 9 (23.7) 6.64 ± 2.34 <0.05*
Note: *The mean AMH levels was compared between PCOS patients who
responded to CC 50 mg vs those who responded to the dose 100 mg
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112.5U daily) than those used for ovulation induction.
When the ‘threshold’ level of FSH for follicular growth is
quickly exceeded and follicle arrest from AMH inhibition
was relieved, resulting in an early visualization of multiple
dominant follicles development.
Our findings are consistent with previous study by
Mahran A and co-workers [21] who have evaluated the
impact of circulating AMH on the success rates of CC
ovulation induction in 60 women with anovulatory
PCOS receiving 187 cycles of treatment, and found
circulating AMH levels to be negatively correlated with
the chances of ovulation. Simially, Amer SA et al. [13]
have evaluated the impact of circulating AMH on the
outcome of ovarian stimulation in 20 women with an-
ovulatory PCOS undergoing 34 cycles of gonadotrophin
treatment. They found circulating AMH levels to be
negatively correlated with ovarian response to human
menopausal gonadotrophin. On the other hand, our
findings concur with those of El-Halawaty et al. [22], in
that AMH levels were significantly higher in responders
to CC therapy when compared to non-responder. How-
ever, their findings included a subgroup of obese PCOS
women receiving a high dose of CC (150 mg/d). Only
25 % of participants in that study ovulated in response
to the high CC in first cycle, which is much lower than
the majority of publications reporting ovulation rates of
75–80 % after CC treatment [8].
AMH was reported to be one of the local inhibitors of
FSH action by decreasing granulosa cell sensitivity to
FSH [23, 24], since the antral follicles from AMH knock-
out mice are more sensitive to FSH than those from the
wild type [25]. This effect of AMH was mainly the result
of inhibited aromatase activity in granulosa cell. In keep-
ing with this study, an inhibitory effect of AMH on
FSH- induced aromatase mRNA expression and estra-
diol production has been shown in human GLCs [26].
Similarly, the inverse relationship between AMH and
estradiol has also been found in PCOS women [6]. The
fact that AMH is inhibitory to factors required for fol-
licle growth and subsequently selection process of the
dominant follicle [3], thus it is not surprising that AMH
is a negatively predictive factor for ovarian response to
CC therapy in PCOS women.
It is of note that AMH, LH, AFC and ovarian
volume are closely related. Furthermore, AFC and
ovarian volume were significantly higher in the CRA
group compared with responder. These may there-
fore be confounding factors that could have an influ-
ence on responsiveness to CC. So we have used
multiple logistic regression analysis to determine
which of these factors is an independent predictor of
ovulation. The analysis has shown that AMH serum
level is the best overall predictor of ovarian response
to CC treatment.
In current study, the AMH levels were significantly
higher in non-pregnancy compared with pregnancy
group. However, this difference was disappeared when
CC-resistant women were excluded from the analyses.
This may be due to the fact that most CC resistant
patients in this study had relatively higher AMH were
excluded from the non-pregnancy group.
In the present study, we found serum AMH levels
with a threshold of 7.77 ng/ml had a sensitivity of 92 %
and specificity of 65 % in predicting ovarian response to
CC. This cut-off is greater than two times those of previ-
ously reported by Mahran A et al. [21] who reported
that 3.4 ng/ml was an optimal cut-off for the prediction
of CRA among 60 women with PCOS. It is possible that
different kits for detecting AMH might result in
substantial variation in the serum level of AMH. In
addition, variations in PCOS manifestations and AMH
across different racial/ethnic backgrounds may be as-
cribed to these differences. Therefore, it should be noted
that our cutoff AMH level applies only to the AMH kit
used in this study. More studies are needed to test which
value would be most useful in clinical practice.
The main strength of this study is its prospective
design with inclusion of anovulatory patients fulfilling
the study inclusion. However, our study has certain limi-
tations that should be noted. Definitions vary the dose
required to define CC-resistance ranging from 100 mg
to150 mg of CC [27, 28]. In the present study, we de-
fined CC-resistance as failure to ovulate in three CC
cycles with the maximum dose 100 mg of CC. The CC
non-responder in our study may ovulate in response to
150 mg of CC administration. However, the doses in
excess of 100 mg per day are not approved by Food
and Drug Administration of United States. Therefore,
we did not prescribe more than 100 mg per day of
CC in this study.
Conclusions
In summary, this study demonstrates that the plasma
AMH can predict ovarian response to CC treatment.
Therefore, measurement of serum AMH concentration
for anovulatory women with PCOS before treatment
may be a useful tool in predicting the outcome of CC
administration. This could help with counselling PCOS
patients concerning the expected success of CC treat-
ment and may render the ovulation-induction protocols
more patient-tailored and more cost-effective.
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